Tango Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Tango Therapeutics' es Barbara Weber , nombrado en Mar 2017, tiene una permanencia de 7.08 años. compensación anual total es $4.68M, compuesta por 12.3% salario y 87.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.3% de las acciones de la empresa, por valor de $10.18M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 3.3 años, respectivamente.
Información clave
Barbara Weber
Chief Executive Officer (CEO)
US$3.4m
Compensación total
| Porcentaje del salario del CEO | 18.5% |
| Permanencia del CEO | 7.2yrs |
| Participación del CEO | 1.3% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$626k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$107m |
| Mar 31 2023 | n/a | n/a | -US$111m |
| Dec 31 2022 | US$5m | US$575k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$92m |
| Mar 31 2022 | n/a | n/a | -US$71m |
| Dec 31 2021 | US$12m | US$514k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$958k | US$492k | -US$52m |
Compensación vs. Mercado: La compensación total ($USD3.39M) de Barbara está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.45M).
Compensación vs. Ingresos: La compensación de Barbara ha sido consistente con los resultados de la empresa en el último año.
CEO
Barbara Weber (66 yo)
7.2yrs
Permanencia
US$3,391,058
Compensación
Dr. Barbara L. Weber, M.D., has been the President, Director and Chief Executive Officer of Tango Therapeutics Inc., since March 2017 and also served as Chairperson. Dr. Weber serves as a Director of OPY A...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.2yrs | US$3.39m | 1.31% $ 10.6m | |
| Chief Financial Officer | 7.6yrs | US$1.52m | 0.070% $ 567.8k | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Founder | no data | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chief Scientific Officer | less than a year | sin datos | sin datos | |
| Chief Legal Officer | 2.8yrs | sin datos | 0.041% $ 333.9k | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Head of Chemistry | 2.3yrs | sin datos | sin datos | |
| President of Research & Development | 1.3yrs | US$3.11m | 0.025% $ 205.5k |
2.3yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TNGX se considera experimentado (2.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 7.2yrs | US$3.39m | 1.31% $ 10.6m | |
| Founder & Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos | |
| Founder & Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos | |
| Independent Chairman | 7.3yrs | US$171.53k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$141.53k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | 3.2yrs | US$148.03k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$139.03k | 0% $ 0 | |
| Independent Director | less than a year | US$375.87k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 3.3yrs | sin datos | sin datos |
3.3yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de TNGX se considera experimentada (3.3 años de antigüedad promedio).